Hans Tesch

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

Gϋnter von Minckwitz, Andreas Schneeweiß, Sibylle Loibl et al. · The Lancet Oncology · 2014 · 1K citations

Medicine, Oncology, Breast Oncology +12

Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

Carsten Denkert, Gϋnter von Minckwitz, Jan C. Brase et al. · Journal of Clinical Oncology · 2014 · 1K citations · Full text

Medicine, Immunology, Oncology +17

Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease

Volker Diehl, Jeremy Franklin, Michael Pfreundschuh et al. · New England Journal of Medicine · 2003 · 833 citations · Full text

Medicine, Oncology, Pharmacology +11

A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

S. Loibl, Michael Untch, Nicole Burchardi et al. · Annals of Oncology · 2019 · 694 citations

Medicine, Oncology, Pharmacology +16

Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients

Brigitte Rack, Christian Schindlbeck, Julia Jückstöck et al. · JNCI Journal of the National Cancer Institute · 2014 · 606 citations · Full text

Medicine, Cancer Biology, Oncology +17